Analysis of patent litigation, PTAB practice, prosecution and pharma IP, written on the data behind LexDana.
Tagged life sciences · clear
Written by : Rhett D. Ramsey & Joseph Mallon, Ph.D. Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals. Novartis Pharm. Corp. v. MSN Pharm. Inc. , Civil Action No.…
Written by : Susan M. Janicki, Ph.D. & Eric Furman, Ph.D. On July 10, the Senate unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S.150), which seeks to increase competition and lower drug prices by imposing limits on patent…
Written by : Brianne M. Kingery & Michael L. Fuller On August 13, 2024, the Federal Circuit issued its decision in Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 24-1061, [1] which limits the scope of obviousness-type double patenting for patents…
Written by : Ari Feinstein & Jane Dai, Ph.D. As we previously discussed , on November 7, 2023, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listings of device…
Written by : Susan M. Janicki, Ph.D. & Agnes Juang, Ph.D. On May 24, 2024, member states of the World Intellectual Property Organization (WIPO) adopted a new treaty on Intellectual Property, Genetic Resources and Associated Traditional Knowledge [1] that…
Written by : Ashley C. Morales & Michael L. Fuller On Friday, June 21, 2024, the FDA updated its Patent Listing Dispute List to indicate that the ten pharmaceutical companies who had received warning letters from the FTC in April did not make changes to…
Written by : Ashley C. Morales & Joseph Mallon, Ph.D. On March 20, 2024, The USPTO issued an alert, notifying practitioners that the USPTO had developed training materials for patent examiners regarding searching for prior art in FDA and NIH databases. [1]…
Written by : Ari Feinstein & Jane Dai, Ph.D. As we recently discussed , the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listing of device patents in the Food and Drug…
Written by : Jacob J. Golan, Ph.D. & Jason J. Jardine On June 6, 2023, the Senate Judiciary Committee's Subcommittee on Intellectual Property introduced a Bill entitled “Patent Eligibility Restoration Act of 2023” (PERA) aiming to amend the…
Written by : Rhett D. Ramsey & Eric Furman, Ph.D. On January 9, 2024, the USPTO published guidelines for its patent examiners when evaluating compliance with the enablement requirement in light of the U.S. Supreme Court’s recent decision in Amgen…
Written by : Brianne M. Kingery & Robert J. Hilton, Ph.D. In a recent precedential opinion, the Court of Appeals for the Federal Circuit vacated an infringement judgement against Mylan ( Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. , No.…
Written by : Ashley C. Morales & Joseph Mallon, Ph.D. In Baxalta Incorporated v. Genentech, Inc. , 2022-1461, the Federal Circuit affirmed the district court’s decision granting Genentech’s motion for summary judgment that claims 1-4, 9, and 20…
